Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: Sequential FDG-PET-CT findings

Radiotherapy and Oncology

Volumn 94, Issue 2, 2010, Pages 151-155

  Janssen, Marco H M ^a   Öllers, Michel C ^a   van Stiphout, Ruud G P M ^a   Buijsen, Jeroen ^a   van den Bogaard, Jørgen ^a   de Ruysscher, Dirk ^a   Lambin, Philippe ^a   Lammering, Guido ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combined radiochemotherapy; Metabolic treatment response; Radiotherapy alone; Rectal cancer; Sequential FDG PET CT imaging

Indexed keywords

CAPECITABINE; FLUORODEOXYGLUCOSE;

ARTICLE; BIOEQUIVALENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HUMAN; METABOLISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77249154009     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.12.033     Document Type: Article

References (37)

1. Kalff V., Duong C., Drummond E.G., Matthews J.P., and Hicks R.J. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 47 (2006) 14-22
2. Cascini G.L., Avallone A., Delrio P., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47 (2006) 1241-1248
3. Capirci C., Rampin L., Erba P.A., et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34 (2007) 1583-1593
4. Capirci C., Rubello D., Chierichetti F., et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol 187 (2006) W202-W208
5. Amthauer H., Denecke T., Rau B., et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31 (2004) 811-819
6. Denecke T., Rau B., Hoffmann K.T., et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol 15 (2005) 1658-1666
7. Guillem J.G., Moore H.G., Akhurst T., et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199 (2004) 1-7
8. Rosenberg R., Herrmann K., Gertler R., et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 24 (2009) 191-200
9. Siegel R., Dresel S., Koswig S., et al. Response to preoperative short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron emission tomography. Onkologie 31 (2008) 166-172
10. Vliegen R.F., Beets-Tan R.G., Vanhauten B., et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?. Strahlenther Onkol 184 (2008) 457-464
11. Janssen M.H., Ollers M.C., Riedl R.G., et al. Accurate prediction of pathological rectal tumor response after 2 weeks of pre-operative radiochemotherapy using FDG-PET-CT imaging. Int J Radiat Oncol Biol Phys (2009) 10.1016/j.ijrobp.2009.04.030
12. Hindie E., Hennequin C., and Moretti J.L. Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management. Eur J Nucl Med Mol Imaging 34 (2007) 1576-1582
13. Valentini V., Coco C., Cellini N., et al. Ten years of preoperative chemoradiation for extraperitoneal T 3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 51 (2001) 371-383
14. Roedl J.B., Colen R.R., Holalkere N.S., Fischman A.J., Choi N.C., and Blake M.A. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 89 (2008) 278-286
15. Petit S.F., Aerts H.J., van Loon J.G., et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother Oncol 91 (2009) 393-398
16. Glimelius B., Gronberg H., Jarhult J., Wallgren A., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42 (2003) 476-492
17. Janssen M.H., Aerts H.J., Ollers M.C., et al. Tumor delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients. Int J Radiat Oncol Biol Phys 73 (2009) 456-465
18. Beaulieu S., Kinahan P., Tseng J., et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 44 (2003) 1044-1050
19. Eary J.F., and Mankoff D.A. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 39 (1998) 250-254
20. Ollers M., Bosmans G., van Baardwijk A., et al. The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiother Oncol 87 (2008) 142-146
21. Daisne J.F., Sibomana M., Bol A., Doumont T., Lonneux M., and Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 69 (2003) 247-250
22. Kostakoglu L., Coleman M., Leonard J.P., Kuji I., Zoe H., and Goldsmith S.J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43 (2002) 1018-1027
23. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
24. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 (2003) 4604-4610
25. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
26. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
27. Direcks W.G., Berndsen S.C., Proost N., et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 99 (2008) 481-487
28. Dimitrakopoulou-Strauss A., Strauss L.G., Burger C., et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 45 (2004) 1480-1487
29. Dimitrakopoulou-Strauss A., Strauss L.G., and Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 47 (2003) 8-13
30. de Geus-Oei L.F., van Laarhoven H.W., Visser E.P., et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19 (2008) 348-352
31. Sharma R.I., and Smith T.A. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport. J Nucl Med 49 (2008) 1386-1394
32. Schoder H., and Ong S.C. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med 38 (2008) 119-128
33. Keyes Jr. J.W. SUV: standard uptake or silly useless value?. J Nucl Med 36 (1995) 1836-1839
34. Langen K.J., Braun U., Rota Kops E., et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34 (1993) 355-359
35. Lindholm P., Minn H., Leskinen-Kallio S., Bergman J., Ruotsalainen U., and Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 34 (1993) 1-6
36. Crippa F., Gavazzi C., Bozzetti F., et al. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 83 (1997) 748-752
37. Kao P.F., Chou Y.H., Lai C.W., and Diffuse F.D.G. Uptake in acute prostatitis. Clin Nucl Med 33 (2008) 308-310